Get Permission Patel, Joshi, Patel, and Modi: Incidence density rate of multidrug-resistant organism (MDRO) at a tertiary care teaching hospital: A retrospective cross-sectional study


Introduction

MDROs are defined as microorganisms that are non-susceptible to one or more classes of antimicrobial agents. As per WHO, carbapenem-resistant Acinetobacter baumannii (CRAB) and Pseudomonas aeruginosa, third-generation or carbapenem-resistant Enterobacteriaceae, vancomycin-resistant Enterococcus spp. and methicillin-resistant Staphylococcus aureus organisms are critical and needs urgent attention.1, 2 MDROs infections are more commonly seen in critically ill patients with prior antimicrobial exposure or who have comorbidities that lead to poor clinical outcomes and death.3 Also many infants in the country are now born with infections caused by resistant strains and these greatly increased infant mortality rates. The Center for Disease Dynamics, Economics and Policy (CDDEP) reported that amongst MDROs, MRSA is rapidly rising worldwide.4, 5 In India, prevalence of MDROs ranges from 30% to 60%.6 Prevalence of extended-spectrum beta-lactamase (ESBL) gram-negative bacilli (GNB) ranges from 19% to 60% and carbapenem-resistant GNB ranges from 5.3% to 59%.7 With a limited treatment options for MDRO, concerns for these infections are increasing and MDRO infections often lead to increased length of stay, costs, and mortality. It is a global health problem that requires urgent action for effective antimicrobial stewardship interventions.1, 2 Without adherence to recommendations for hand hygiene and use of gloves, health care personnel (HCP) transmit MDROs to patients in great extent. Thus, strategies to increase adherence to standard precautions and monitor the trends are identified as important components of MDRO control programs. Preventing infections will reduce the burden of MDROs in healthcare settings.2

There is a lack of screening and reporting for MDRO infections in Indian hospitals. Therefore, the objective of the present study was to determine the MDRO infection incidence density rate (IDR) and trend of MDRO infections at our hospital. It will also provide a benchmark for similar facilities using the same surveillance definitions and methodology.

Materials and Methods

The study was conducted after the approval of the Institutional Ethics Committee. This was a retrospective cross-sectional study, carried out at the Microbiology laboratory of Central Diagnostic Laboratory (CDL), an NABL-accredited laboratory of Shree Krishna Hospital and Pramukhswami Medical College, Bhaikaka University, Karamsad. The culture data from January 2014 to December 2023 was analyzed to determine the MDRO IDR per1000 patient-days and trend of MDRO infections which included Methicillin-resistant Staphylococcus aureus (MRSA), Vancomycin-resistant Enterococci (VRE), Carbapenem-resistant Enterobacterales (CRE), Multidrug-resistant (MDR) Acinetobacter spp. and MDR Pseudomonas aeruginosa. All clinical isolates from all age groups were included in the study. Participants in whom the same isolates were previously isolated from culture and were suggestive of persistent infection were excluded from the study.

All the clinical specimens such as urine, sputum, endotracheal & tracheal aspirate, broncho-alveolar lavage, pus, blood, and sterile body fluids (pleural fluid, cerebrospinal fluid, ascitic fluid etc..) received for culture and antimicrobial susceptibility test were processed as per the standard protocol. Conventional culture methods and the BacT/ALERT® 3D Microbial Detection System (BioMerieux, France) were used and the isolates were processed for identification and antimicrobial susceptibility tests by the Vitek 2 Compact system (BioMerieux, France) as per the CLSI guidelines.8

The following definitions were used to consider MDRO and were calculated per 1000 patients-days.9

  1. MRSA: Staphylococcus aureus cultured from any specimen that tested oxacillin-resistant, cefoxitin-resistant, or methicillin-resistant by standard susceptibility testing methods were considered as MRSA.

  2. VRE: Enterococcus faecalis, Enterococcus faecium, or Enterococcus spp. that was resistant to vancomycin, by standard susceptibility testing methods were considered as VRE.

  3. CRE: Escherichia coli, Klebsiella oxytoca, Klebsiella pneumoniae, Klebsiella aerogens or Enterobacter spp. resistant to imipenem, meropenem, doripenem, ertapenem by standard susceptibility testing methods were considered as CRE.

  4. MDR-Acinetobacter spp. & MDR Pseudomonas aeruginosa (P. aeruginosa): Acinetobacter spp. & P. aeruginosa isolates non-susceptible (specifically, either resistant or intermediate) to at least one agent in at least 3 antimicrobial classes of the following 6 antimicrobial classes: Aminoglycosides (Amikacin, Gentamicin, Tobramycin) Carbapenems (Imipenem Meropenem Doripenem), Fluoroquinolones (Ciprofloxacin, Levofloxacin), β-lactam/β-lactam β-lactamase inhibitor combination (Piperacillin-tazobactam), Cephalosporins (Cefepime, Ceftazidime, Cefoxitin, Ceftriaxone), Sulbactam (Ampicillin-sulbactam) were considered as MDR- Acinetobacter & MDR P. aeruginosa.

  5. Overall MDRO IDR (cases/per 1000 patient-days) = Total MDRO during the observation period / total numbers of inpatient days during the observation period *1000. Similarly, IDR of MRSA, VRE, CRE, MDR-Acinetobacter spp. & MDR P. aeruginosa was calculated per 1000 patient-days.

Data collection and analysis

The data of all culture-positive samples from which MDRO has been isolated was collected from the Laboratory & hospital information system. Data were analyzed using Microsoft® Excel for Mac version 16.79.2 (23112723).

Results

A total of 7311 MDRO were detected from 1321793 in-patients, showing the overall IDR of 5.53 per 1000 patients-days. CRE (n = 3056, 42%) was the most common MDRO (Figure 1). The overall IDR per 1000 patient-days of MRSA, VRE, CRE, MDR- Acinetobacter spp., and MDR- P. aeruginosa has been shown in Table 1. Overall MDRO IDR has increased from 4.20 to 8.77 from 2014 to 2023 (Figure 2). An increasing IDR was observed for MRSA and MDR- P. aeruginosa isolates (Figure 3, Figure 4, Figure 5, Figure 6, Figure 7). As per Figure 6, around 80% of the Acinetobacter spp. were MDR as compared to other MDRO.

Figure 1

% Distribution of various MDRO (n=7311)

https://typeset-prod-media-server.s3.amazonaws.com/article_uploads/f0364c19-b92d-45f8-8d9a-5277055221e6/image/d414b607-9f65-4eca-a212-80dfb474eadd-uimage.png

Figure 2

Year-wise trend of MDRO/1000 patient-days

https://typeset-prod-media-server.s3.amazonaws.com/article_uploads/f0364c19-b92d-45f8-8d9a-5277055221e6/image/fc85be8d-8020-4f9a-bcf8-6deda5a77fe2-uimage.png

Figure 3

Year-wise trend of MRSA

https://typeset-prod-media-server.s3.amazonaws.com/article_uploads/f0364c19-b92d-45f8-8d9a-5277055221e6/image/bcb42608-0c32-4b95-8042-108fe04c56e3-uimage.png

Figure 4

Year-wise trend of VRE

https://typeset-prod-media-server.s3.amazonaws.com/article_uploads/f0364c19-b92d-45f8-8d9a-5277055221e6/image/b0467f21-f374-4755-b1e5-18a1c420c5d0-uimage.png

Figure 5

Year-wise trend of CRE

https://typeset-prod-media-server.s3.amazonaws.com/article_uploads/f0364c19-b92d-45f8-8d9a-5277055221e6/image/ab157500-a68f-415f-bdee-f38b6a343806-uimage.png

Figure 6

Year-wise trend of MDR Acinetobacter spp.

https://typeset-prod-media-server.s3.amazonaws.com/article_uploads/f0364c19-b92d-45f8-8d9a-5277055221e6/image/7d1af0a1-a14f-49d4-8019-4d0a2f0c1b23-uimage.png

Figure 7

Year-wise trend of MDR P. aeruginosa

https://typeset-prod-media-server.s3.amazonaws.com/article_uploads/f0364c19-b92d-45f8-8d9a-5277055221e6/image/e0c6a4d7-f9e0-4ad8-a302-aab9cceb95ac-uimage.png

Table 1

Overall incidence density rate (IDR) of MDROs per 1000 patient-days (2014-2023)

Type of MDROs

Overall incidence density rate (IDR)

Methicillin-resistant Staphylococcus aureus (MRSA)

0.81

Vancomycin-resistant Enterococcus spp. (VRE)

0.23

Carbapenem-resistant Enterobacterales (CRE)

2.31

MDR - Acinetobacter spp.

1.29

MDR - P. aeruginosa

0.89

Discussion

Globally, it has been observed that infections caused by antimicrobial-resistant organisms is emerging nowadays. It represents a serious health problem for both healthcare practitioners and patients. There are various risk factors for acquiring infection with MDROs such as lack of knowledge regarding organisms and their antimicrobial susceptibility pattern, rampant use of unreasonable fixed drug combinations, long-term use of antimicrobial therapy, poor infection control practices, prolonged length of hospital stay, invasive procedures, and colonization. MDR bacteria can cause various types of infections such as pneumonia, urinary tract, wound infections, and septicemia and are associated with an increase in mortality and morbidity.5, 10, 11, 12 One large, multicentre observative cohort study provided data on the morbidity & mortality of healthcare associated infections (HAIs) with multidrug-resistant bacteria in Germany and found that 1.6 per 1000 patients suffered a HAI with an MDRO and 0.1 per 1000 patients died as a result of it.13 Therefore, monitoring incidence density rate & trend analysis of various MDROs is important for the control of infection and for implementing the institutional antimicrobial stewardship program in India.

In the present study, overall MDRO infection IDR was 5.53 per 1000 patient-days which was lower than the published studies where MDRO were detected in 26,499 of all in-patients (37.1 per 1000 in-patients).13 In our study, Hospital acquired (HAI) MDRO infection rate has not been analyzed separately. However, published studies mention varied rates of HAI MDRO infection IDR ranging from 0.97 - 4.8 per 1000 in-patients.13, 14, 15 Prevalence of CRE was most common followed by MDR- Acinetobacter spp. in the present study. Similar to this, Carbapenem resistant Klebsiella pneumoniae (CRKP) was responsible for 35.40% of HAIs caused by MDROs.15

MRSA

During the study period, we observed increase in the IDR of MRSA from 0.57 to 1.48 per 1000 patient-days. However, it is lower than the findings of the study where overall MRSA colonization and/or infection was 16.5/1000 patients-days and 0.5/1000 patient-days for HAI MRSA.13 Contrary to this, a recent study reported an overall stable and rather decreasing MRSA IDR in both ICU & non-ICU settings indicating geographic disparities, variations and complex factors influencing MRSA rates.16 Published studies across India shows that the trend of MRSA is increasing from 26.14% to 85%.2, 6, 17 The variations in prevalence could be due to different geographical areas, and the study methodology. A surveillance study conducted by Wattal et al, reported that the prevalence of MRSA was 78% in their study. It could be because of the high usage of cephalosporins and quinolones.2 Lohan et al, found the prevalence of MRSA rising from 28% to 35.1% among patients undergoing surgery followed by admission to ICUs. This increasing trend is due to the carriage of MRSA by HCWs & patients, use of indwelling devices, diversity in mecA gene, poor compliance to hand hygiene, lack of surveillance and lack of compliance to care bundle.17 However, the risk factors for acquiring the MRSA were not analyzed in the present study.

VRE

In the present study, IDR of VRE isolates has increased from 0.02 to 0.27 per 1000 patient-days at our institute. However, it is lower than the findings of the study where overall VRE colonization and/or infection was 6.3/1000 patients-days.13 A recent study reported increase in VRE rates from 0.25 to 0.63 per 1000 patient-days. Disruption of certain infection control measures and inappropriate use of vancomycin and third-generation cephalosporins may contribute to this phenomenan.16 Similar to our findings, a published study mentioned the prevalence of VRE from 0.4% to 35.5% around the world.10, 17 In Asian regions, the prevalence rate of VRE ranges from 1% to 27.70% including in India.17, 18 Such high prevalence could be due to, organisms being transmitted to humans through animal food as well as the fecal-oral route through contaminated water and food as many mammals and birds have reservoirs of enterococci, exposure to the broad-spectrum antibiotic, length of hospital stays, and a breach in hospital infection control.2, 18

CRE

Carbapenems are used to treat infections caused by ESBL-producing organisms. A new class of carbapenemases emerged in 1996.2 The increased prevalence of CRE has been associated with high mortality and is a global public health problem.19 In the present study, IDR of CRE isolates increased from 1.66 to 3.89 per 1000 patient-days and were the most common MDRO at our institute. Similar to our findings, incidence of CRE has increased in published studies.6, 16, 19 However, lower carbapenem resistance has also been reported by a published study due to adherence to hospital antibiotics stewardship programme.20

MDR- Acinetobacter spp.

Hospital-acquired & community-acquired infection caused by Acinetobacter baumannii is a major challenge to the healthcare system as this organism is becoming resistant to a large group of antibiotics although some strains show resistance to all antibiotics and contribute to increased morbidity and mortality.21, 22 Many outbreaks were reported globally by the MDR strain of Acinetobacter spp. As per the CDC report of 2013, each year approximately 7000 infections and 500 deaths are caused by MDR Acinetobacter. Infections caused by carbapenem-resistant strains have been associated with high death rates.23 The prevalence of MDR Acinetobacter spp. from 29% up to 74% was mentioned by different published studies.22, 23 A recent study also observed that ICU & Non-ICU had very significant increases in CRAB BSI IDR. The global rise in CRAB during the pandemic is a matter of concern.16 However, we didn’t observe any change in the trend in MDR Acinetobacter spp. (1.52 to 1.53 per 1000 patient-days) during the present study. Around 80% of the Acinetobacter spp. were MDR as compared to other MDRO in the present study. Similar to this, A. baumanni isolates detected during the study period were almost resistant to all the drugs being tested.14

MDR- P. aeruginosa

In the US, published data suggest that 13 - 19% of hospital-acquired infections were caused by MDR- P. aeruginosa each year amongst them the estimated mortality was 46.1%. In the present study, we found that the IDR of MDR- P. aeruginosa increased from 0.43 to 1.60 per 1000 patient-days. Similar to this, a significant increase (187%) in carbapenem-resistant P. aeruginosa (CRPA) BSI IDR was observed in non-ICU during the study period.16 Concordance to our findings, published studies show that the rate of MDR- P. aeruginosa has increased in the U.S (4 to 14%), and Italy (2.1 to 4.1%). 24 Other published studies showed a very high prevalence of 76.8% MDR- P. aeruginosa in burns patients which is a cause of concern.25 Whereas the low prevalence, 9%, 14% & 19.5%, of MDR- P. aeruginosa was also mentioned by published studies.6, 10, 26

As the spread of MDRO is the biggest threat, urgent drug-resistant bacterial countermeasures are needed. Among the drug-resistant bacteria, CRE and CRAB are some of the most important drug-resistant bacteria to deal with, and the outline of the infectious diseases caused by such bacteria will be useful for their control in future.27 To prevent of spread of MDRO, contact precautions, single room isolation and dedicated specific staff should be given a consideration to patients with multiple drug-resistant organisms (MDROs) in ICUs. However, isolation and cohorting strategies cannot be implemented in all cases; especially in open-plan ICUs.28 One semi-experimental study found that the comprehensive multi-model strategies including behavioral aspects of health care personnel, continual training programs, regular feedback, and environment control reduced the incidence of HAIs and the HAIs caused by MDROs in rehabilitation units.15 One Health approach, as defined by the World Health Organization, is the strategy that involves the collaboration of multiple sectors to improve public health outcomes. Whole-genome sequencing (WGS) studies can be a useful tool for understand the spreading dynamics of MDRO and can help in limiting their spread. The analysis of resistome and virulome by WGS, can help the infection control team to strengthen the surveillance mechanisms.29

Our study is one of the very few studies to establish infection incidence density rates & trends of various MDRO among inpatients in a tertiary care hospital. There are some limitations of our study. Being a retrospective study, we couldn’t study location-wise and organism-wise distribution of MDRO which might have been useful in taking site-specific appropriate infection control measures to prevent the spread of such organisms.

Conclusions

MDROs have been identified as a significant problem at our institute showing an increasing trend. We recommend following stringent infection control practices including isolation protocols as well as adherence to hospital antibiotic policy to reduce the burden of MDROs.

Author Contributions

Authors have made substantial contributions to the conception, design of the work, the acquisition, analysis & interpretation of the data and drafting the work and substantively revising it. All authors have met the ICMJE's requirements for authorship. The paper represents their honest efforts, and that they are able to independently validate the accuracy of the data presented.

Sources of Funding

None.

Data Availability Statement

The study did not report any data. 

Conflicts of Interest

The authors declare no conflicts of interest.

References

1 

B Anaya-Baz N Maldonado ZR Palaciosbaena V Palomo M Diletta Pezzani S Chiesi Systematic literature review of the burden and outcomes of infections due to multidrug-resistant organisms in Europe: the ABOUT-MDRO project protocolBMJ Open2020105e030608

2 

C Wattal N Goel JK Oberoi R Raveendran S Datta KJ Prasad Surveillance of multidrug resistant organisms in tertiary care hospital in Delhi, IndiaJ Assoc Physicians India201058326

3 

S Gandra KK Tseng A Arora B Bhowmik ML Robinson B Panigrahi The mortality burden of multidrug-resistant pathogens in India: a retrospective, observational studyClin Infect Dis201969456370

4 

S Kalluru S Eggers A Barker D Shirley AK Sethi S Sengupta Risk factors for infection with multidrug-resistant organisms in Haryana, IndiaAm J Infect Control20184633415

5 

Á Rodríguez-Villodres C Martín-Gandul G Peñalva AB Guisado-Gil JC Crespo-Rivas ME Pachón-Ibáñez Prevalence and risk factors for multidrug-resistant organisms colonization in long-term care facilities around the world: a reviewAntibiotics (Basel)2021106680

6 

V Kaniyarakkal SB Variamkandi K George BP Jose Microbiological Profile of Significant Multi-Drug Resistant Organisms Isolated in a Tertiary Care Centre, Kerala, IndiaIndian J Med Microbiol20218540411

7 

CLSI Performance Standards for Antimicrobial Susceptibility Testing34th edClinical and Laboratory Standards InstituteWayne, PA2024

8 

V Nagvekar S Sawant S Amey Prevalence of multi drug resistant Gram-negative bacteria cases at admission in multispecialty hospitalJ Glob Antimicrob Resist20202245761

9 

Centers for Disease Control and Prevention Multidrug-Resistant Organism & Clostridioides difficile (MDRO/CDI) Infection Surveillance and LabID Event Reporting Module20211251https://www.cdc.gov/nhsn/psc/cdiff/index.html

10 

M Wang H Wei Y Zhao L Shang L Di C Lyu Analysis of multidrug-resistant bacteria in 3223 patients with hospital-acquired infections (HAI) from a tertiary general hospital in ChinaBosn J Basic Med Sci20191918693

11 

C Wattal N Kler JK Oberoi A Fursule A Kumar A Thakur Neonatal Sepsis: Mortality and Morbidity in Neonatal Sepsis due to Multidrug-Resistant (MDR) Organisms: Part 1Indian J Pediatr202087211721

12 

S Qureshi N Maria M Zeeshan S Irfan FN Qamar Prevalence and risk factors associated with multi-drug resistant organisms (MDRO) carriage among pediatric patients at the time of admission in a tertiary care hospital of a developing country. A cross-sectional studyBMC Infect Dis2009211547

13 

A Neubeiser M Bonsignore S Tafelski C Alefelder K Schwegmann H Rüden Mortality attributable to hospital acquired infections with multidrug-resistant bacteria in a large group of German hospitalsJ Infect Public Health202013220410

14 

K Baig SMS Din NA Elkkhizzi DJA Nakhli Incidence of Hospital Acquired Multidrug Resistant Organisms in a Tertiary Care FacilityJ Infect Dis Epidemiol20151115

15 

S Li J Lin S Tao L Guo W Huang J Li Multi-Model Strategies for Prevention of Infection Caused by Certain Multi-Drug Resistant Organisms in A Rehabilitation Unit: A Semi-Experimental StudyAntibiotics (Basel)20231271199

16 

P Karakosta S Vourli E Kousouli G Meletis A Tychala C Louka Multidrug-resistant organism bloodstream infection and hospital acquisition among inpatients in three tertiary Greek hospitals during the COVID-19 eraEur J Clin Microbiol Infect Dis202443612416

17 

K Lohan J Sangwan P Mane S Lathwal Prevalence pattern of MRSA from a rural medical college of North India: a cause of concernJ Family Med Prim Care20211027527

18 

S Shrestha S Kharel S Homagain R Aryal SK Mishra Prevalence of vancomycin-resistant enterococci in Asia-A systematic review and meta-analysisJ Clin Pharm Ther2021465122637

19 

D Chotiprasitsakul S Srichatrapimuk S Kirdlarp AD Pyden P Santanirand Epidemiology of carbapenem-resistant Enterobacteriaceae: a 5-year experience at a tertiary care hospitalInfect Drug Resist2019124618

20 

P Datta V Gupta S Garg J Chander Phenotypic method for differentiation of carbapenemases in Enterobacteriaceae: study from north IndiaIndian J Pathol Microbiol201255335760

21 

S Begum F Hasan S Hussain AA Shah Prevalence of multi drug resistant Acinetobacter baumannii in the clinical samples from Tertiary Care Hospital in IslamabadPak J Med Sci201329512538

22 

R Kaur S Kaur L Oberoi M Wajid Prevalence & antimicrobial profile of acinetobacter Spp. isolated from tertiary care hospitalInt J Contemp Med Res20218216

23 

Z Ayenew E Tigabu E Syoum S Ebrahim D Assefa E Tsige Multidrug resistance pattern of Acinetobacter species isolated from clinical specimens referred to the Ethiopian Public Health Institute: 2014 to 2018 trend anaylsisPLoS One2021164250896

24 

B Mirzaei ZN Bazgir HR Goli F Iranpour F Mohammadi R Babaei Prevalence of multi-drug resistant (MDR) and extensively drug-resistant (XDR) phenotypes of Pseudomonas aeruginosa and Acinetobacter baumannii isolated in clinical samples from Northeast of IranBMC Res Notes2020131380

25 

P Bhatt K R Rathi S Hazra A Sharma V Shete Prevalence of multidrug resistant Pseudomonas aeruginosa infection in burn patients at a tertiary care centreIndian Journal of Burns20152315659

26 

L Nguyen J Garcia K Gruenberg C Macdougall Multidrug-Resistant Pseudomonas Infections: Hard to Treat, But Hope on the Horizon?Curr Infect Dis Rep201820823

27 

Y Akeda Current situation of carbapenem-resistant Enterobacteriaceae and Acinetobacter in Japan and Southeast AsiaMicrobiol Immunol202165622937

28 

S Iordanou L Palazis C Timiliotou-Matsentidou M Mendris V Raftopoulos When Multidrug-Resistant Organism (MDRO)-Positive ICU Patient Isolation and Cohorting Is Not Feasible, What Comes Next?Cureus2021133e13636

29 

SD Lodovico T Fasciana MD Giulio L Cellini A Giammanco GM Rossolini Spread of Multidrug-Resistant MicroorganismsAntibiotics (Basel)2022117832



jats-html.xsl


This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

  • Article highlights
  • Article tables
  • Article images

Article History

Received : 22-06-2024

Accepted : 27-06-2024


View Article

PDF File   Full Text Article


Copyright permission

Get article permission for commercial use

Downlaod

PDF File   XML File   ePub File


Digital Object Identifier (DOI)

Article DOI

https://doi.org/ 10.18231/j.ijmr.2024.020


Article Metrics






Article Access statistics

Viewed: 772

PDF Downloaded: 357